Sanofi India Ltd
Sanofi India Ltd is a pharmaceutical company engaged in the development, manufacturing, and distribution of prescription medicines and vaccines, primarily serving the Indian market.
Business. Sanofi India Ltd (SANO.NS) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm operates within the broader pharmaceuticals and medical research industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the National Stock Exchange of India. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sanofi India Ltd (SANO.NS) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm operates within the broader pharmaceuticals and medical research industry, generating revenue primarily through product sales. Headquartered in India, the company is listed on the National Stock Exchange of India. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.
Sanofi India Ltd maintains a strong liquidity position, with a current ratio of 1.63 and cash and equivalents amounting to INR 2.3 billion. The company's liquidity risk is assessed as low, supported by its operating cash flow of INR 4.38 billion and minimal long-term debt of INR 178 million. However, the company reported negative free cash flow of INR -1.04 billion, primarily due to capital expenditures of INR -257 million.
The company's profitability is robust, with a return on equity (ROE) of 43.61% and a return on assets (ROA) of 26.04%. These figures significantly exceed the typical benchmarks for the pharmaceutical industry, indicating efficient use of equity and assets. The gross profit margin stands at 50.0%, while the operating margin is 23.3%, both of which are in line with industry norms.
Sanofi India Ltd's revenue is concentrated in a single geographic segment, India, which accounts for 100% of its total revenue. The company does not disclose revenue by product segments, but its primary business is in prescription medicines and vaccines. This geographic concentration exposes the company to regulatory and macroeconomic risks specific to the Indian market.
The company's growth trajectory is stable, with no significant revenue growth or decline reported in the latest financial period. The company's outlook for the current fiscal year is neutral, with no projected changes in revenue or operating income. Analysts have provided a mean price target of INR 4,656, with a median of INR 4,487, suggesting a generally positive sentiment.
The risk assessment for Sanofi India Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio is 0.02, indicating a conservative capital structure. The company has not issued new shares recently, and there are no indications of near-term dilution pressure.
Recent events and disclosures for Sanofi India Ltd include standard financial reporting and analyst estimates. There are no material events or regulatory actions reported in the latest filings that would significantly impact the company's operations or financial position.
- Sanofi India Ltd has a strong liquidity position with a current ratio of 1.63 and INR 2.3 billion in cash and equivalents.
- The company's profitability is robust, with ROE of 43.61% and ROA of 26.04%, significantly above industry norms.
- Revenue is entirely concentrated in the Indian market, exposing the company to local regulatory and macroeconomic risks.
- Analysts have a generally positive outlook, with a mean price target of INR 4,656 and a median of INR 4,487.
- The company has low liquidity and dilution risks, with no immediate filing-based flags and a conservative debt-to-equity ratio of 0.02.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 168,03 |
| Revenue | —no estimate | —no estimate | 19,4B INR |
| Operating income | —no estimate | —no estimate | 5,4B INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Sanofi India Ltd Market data — financials · 2026-05-29
- Sanofi India Ltd Market data — analyst estimates · 2026-05-29
- Sanofi India Ltd Market data — ESG · 2026-05-29